GLP-1 Evidence

Sábháilteacht

Éifeachtaí taobh GLP-1, rangaithe de réir minicíocht

Tá fo-iarsmaí gastrointestinal gar do bheith uilíoch agus de ghnáth is féidir iad a bhainistiú. Is iad na himeachtaí rómhaire a dhéanann an clúdach a bheith rómhaire.

Updated 4 min read 27 citations Evidence strength 4/5

Radharc os cionn leaba ospidéil agus lóistín i seomra leapa roinnte
玄史生 · CC0 · Wikimedia Commons

Na cinn coitianta

Beagnach gach rud coitianta atá gastrointestinal, agus beagnach gach rud a leanann go díreach ó dhóthain gásta moillithe. Ar fud na gclár trialach tá an patrún comhoiriúnach [5][6][8]:

Bannaí minicíochta tipiciúla ó na trialacha randamacha
ÉifeachtCé chomh coitiantaPatrún
TinnisAn-chomhoiriúnach (tríú go leath)Bíonn sé ag ardú tar éis gach céim dosed, ansin socraíonn sé
DíthreabhadhCoitiantaGo minic go luath, de ghnáth sealadach
ConstipáisiúnCoitiantaFéadann sé leanúint; de ghnáth an gearán níos annoying fadtéarmach
LaigeCoitiantaGo láidir gaolmhar le dosed
Pian abdominal, reflux, builleCoitiantaDe ghnáth éadrom
Freagairtí ag an suíomh instealltaNeamhchoitiantaÉadrom
Ag stopadh mar gheall ar fho-iarsmaíCúpla faoin gcéadNíos airde ag na dosanna is airde

Is é an bearna idir "tríú de na daoine a bhraitheann tinn" agus "cúpla faoin gcéad a stopann" an uimhir is úsáideach anseo. Is é an chuid is mó de na daoine a fhaigheann tinn a choinníonn ar aghaidh, de ghnáth mar gheall ar a fheabhsú.

Na cinn rómhaire a bhfuil imní orthu daoine

Is é pancreatitis, galar gallbladder, tumhair C-cell thyroid agus gastroparesis a dhéanann an plé ar líne a bheith rómhaire i bhfad as comhoiriúnacht lena n-uimhir sa sonraí.

  • Galar gallbladder. Go fírinneach méadaithe, ach is é seo go mór toradh ar chailliúint meáchain tapa féin seachas tocsain dhíreach na druga — ardú meáchain tapa le haon bhealach a mhéadaíonn riosca gallstones.
  • Pancreatitis. Faire go dian ar fud an ghrúpa. Níor tháinig an t-aistriú a mhol na tuairiscí cás luath ó na meta-anailísí móra ar trialacha toradh cardiovascular agus duáin [1].
  • Tumhair C-cell thyroid. Tagann an rabhadh ó staidéir ar chreachadóirí. Níor aistríodh é go comhartha daonna a léirigh, ach is é an fáth a bhfuil na drugaí contraindicated le stair phearsanta nó teaghlaigh de carcinoma thyroid medullary nó MEN2.
  • Gastroparesis. Is é moill gásta an meicníocht atá beartaithe, mar atá clúdaithe ar an leathanach meicníocht. Is rud difriúil agus i bhfad níos rómhaire é gastroparesis trom agus leanúnach.

Neamhlaige comharthaí sábháilteachta móra i sonraí trialach comhoibrithe

Conas a looks na gníomhairí óra nua

Tá na gníomhairí beag-móilín óra tar éis dul trí na trialacha randamacha móra i gcoitinne agus i dtíoróid 2 luath [2][3][4]. Tá a próifíl tolra cosúil leis na hinstealltaí — atá faoi smacht ag na fo-iarsmaí gastrointestinal céanna, le straitéis céanna méadú dosed. Ní athraíonn a bheith ina phill an meicníocht, agus dá bhrí sin ní athraíonn sé na fo-iarsmaí. Tuilleadh ar na roghanna óra.

Cén áit a dtéann sonraí trialach agus an saol réalaíoch i dtaithí

Tá na daonraí trialach scagtha, maoirseachta agus méadaithe ar phrótacal. Fuair athbhreithniú 2025 ar úsáid agus éifeachtacht sa saol réalaíoch go bhfuil an pictiúr sábháilteachta forleathan ag seasamh lasmuigh de na trialacha, ach le níos mó éagsúlachta — ábhartha le méadú níos tapúla, stopanna dosed, bearnaí soláthair agus táirgí comhoibrithe le hábhar neamhchinnte [9]. Is é an chuid is mó de na torthaí is measa a thuairiscítear lasmuigh de na trialacha a bhaineann le foinsí neamh-oifigiúla seachas na drugaí féin.

Táibléid le scannán bán atá i gcoimeádán blistéir
Cindy Shebley · CC BY 2.0 · Wikimedia Commons

Ceisteanna coitianta

An bhfuil an tinnis riamh ag dul ar shiúl go hiomlán?
Do na daoine is mó socraíonn sé laistigh de sheachtainí de dosed áirithe, agus tagann sé ar ais go hachomair ag gach méadú. Is é constipation an éifeacht is dóichí a leanfaidh.
An bhfuil caillteanas gruaige mar fho-iarsma?
Is é an t-íseal gruaige toradh aitheanta de chailliúint meáchain tapa go ginearálta — telogen effluvium — seachas tocsain dhíreach na druga. De ghnáth bíonn sé sealadach.
An gcaithfidh mé stopadh roimh an máinliacht?
Iarr ar do anaesthetist. Tá treoir shonrach perioperative ann mar gheall ar d'fhéadfadh an stómach a bheith neamh-íseal tar éis laige caighdeánach.
An bhfuil fo-iarsmaí ag brath ar an gcaoi a bhfuil sé ag obair?
Níl. Tá tinnis agus cailliúint meáchain araon gaolmhar le dosed, ach tá éagsúlacht mhór ag daoine i mbeirt. Tá go leor daoine a chailleann a lán meáchain gan mórán tinnis.
An cruthúnas atá taobh thiar den leathanach seo Bar dhíreach a thaispeánann comhoibriú na 12 foilsitheachta a luaitear ar an leathanach seo de réir cineál staidéir. 1911meta-analysis (1)randomised trial (9)review (1)other (1)
9 foilsithe, 2018–2025. Tá trialacha anseo ach beagán comhoibrithe, mar sin tá tábhacht mhór ag baint le torthaí aonair agus d'fhéadfadh siad a bheith in ann athrú. Téarma: liosta luaiteanna féin an leathanach seo, thíos.

References

Every citation below links to the original peer-reviewed record on PubMed or via DOI. Nothing here is a substitute for medical advice.

  1. Efficacy of tirzepatide, lanifibranor, and resmetirom in metabolic dysfunction-associated steatotic liver disease: a meta-analysis of high-quality randomized controlled trials Zhao S, Tian F, Yu L, et al. · Internal and emergency medicine · 2026 · Meta-analysis DOIPubMed 41917519
  2. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials Badve SV, Bilal A, Lee MMY, et al. · The lancet. Diabetes & endocrinology · 2025 · Meta-analysis DOIPubMed 39608381
  3. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials Karagiannis T, Malandris K, Avgerinos I, et al. · Diabetologia · 2024 · Meta-analysis DOIPubMed 38613667Full text
  4. Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis Stefanou MI, Theodorou A, Malhotra K, et al. · European stroke journal · 2024 · Meta-analysis DOIPubMed 38400569Full text
  5. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis Yamada T, Wakabayashi M, Bhalla A, et al. · Cardiovascular diabetology · 2021 · Meta-analysis DOIPubMed 33413348Full text
  6. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials Kristensen SL, Rørth R, Jhund PS, et al. · The lancet. Diabetes & endocrinology · 2019 · Meta-analysis DOIPubMed 31422062
  7. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial Rosenstock J, Yabe D, Cox D, et al. · Lancet (London, England) · 2026 · Randomised controlled trial DOIPubMed 41765029
  8. Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials Cummings JL, Atri A, Sano M, et al. · Lancet (London, England) · 2026 · Randomised controlled trial DOIPubMed 41865758
  9. Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study Buse JB, Bajaj HS, Dalskov SM, et al. · The lancet. Diabetes & endocrinology · 2026 · Randomised controlled trial DOIPubMed 42251859
  10. Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial Hannon TS, Chao LC, Barrientos-Pérez M, et al. · Lancet (London, England) · 2025 · Randomised controlled trial DOIPubMed 40975112
  11. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes Rosenstock J, Hsia S, Nevarez Ruiz L, et al. · The New England journal of medicine · 2025 · Randomised controlled trial DOIPubMed 40544435
  12. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment Wharton S, Aronne LJ, Stefanski A, et al. · The New England journal of medicine · 2025 · Randomised controlled trial DOIPubMed 40960239
  13. Dose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial Blüher M, Rosenstock J, Hoefler J, et al. · Diabetologia · 2024 · Randomised controlled trial DOIPubMed 38095657Full text
  14. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials Butler J, Shah SJ, Petrie MC, et al. · Lancet (London, England) · 2024 · Randomised controlled trial DOIPubMed 38599221Full text
  15. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial Deanfield J, Verma S, Scirica BM, et al. · Lancet (London, England) · 2024 · Randomised controlled trial DOIPubMed 39181597
  16. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity Wharton S, Blevins T, Connery L, et al. · The New England journal of medicine · 2023 · Randomised controlled trial DOIPubMed 37351564
  17. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial Heise T, Mari A, DeVries JH, et al. · The lancet. Diabetes & endocrinology · 2022 · Randomised controlled trial DOIPubMed 35468322
  18. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial Inagaki N, Takeuchi M, Oura T, et al. · The lancet. Diabetes & endocrinology · 2022 · Randomised controlled trial DOIPubMed 35914543
  19. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial Rosenstock J, Wysham C, Frías JP, et al. · Lancet (London, England) · 2021 · Randomised controlled trial DOIPubMed 34186022
  20. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes Frías JP, Davies MJ, Rosenstock J, et al. · The New England journal of medicine · 2021 · Randomised controlled trial DOIPubMed 34170647
  21. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes Thomas MK, Nikooienejad A, Bray R, et al. · The Journal of clinical endocrinology and metabolism · 2021 · Randomised controlled trial DOIPubMed 33236115Full text
  22. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial Yamada Y, Katagiri H, Hamamoto Y, et al. · The lancet. Diabetes & endocrinology · 2020 · Randomised controlled trial DOIPubMed 32333875
  23. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial Gerstein HC, Colhoun HM, Dagenais GR, et al. · Lancet (London, England) · 2019 · Randomised controlled trial DOIPubMed 31189511
  24. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept Coskun T, Sloop KW, Loghin C, et al. · Molecular metabolism · 2018 · Randomised controlled trial DOIPubMed 30473097Full text
  25. Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies Thomsen RW, Mailhac A, Løhde JB, et al. · Diabetes, obesity & metabolism · 2025 · Review DOIPubMed 40196933Full text
  26. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials Sattar N, Lee MMY, Kristensen SL, et al. · The lancet. Diabetes & endocrinology · 2021 · Journal article DOIPubMed 34425083
  27. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes Aroda VR, Rosenstock J, Terauchi Y, et al. · Diabetes care · 2019 · Journal article DOIPubMed 31186300

This page was translated automatically from English. The citations and numbers are unchanged. Read the English original if anything reads oddly. Read the English original